Senaparib

Overview of the drug Senaparib

Senaparib
[[File: Chemical structure of Senaparib |frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Senaparib is a PARP inhibitor that is being investigated for its potential use in the treatment of various types of cancer. It is a small molecule that targets the poly (ADP-ribose) polymerase (PARP) enzyme, which plays a critical role in the repair of DNA damage in cells. By inhibiting this enzyme, Senaparib can enhance the effects of DNA-damaging agents and promote cancer cell death.

Mechanism of Action

Senaparib works by inhibiting the activity of the PARP enzyme. PARP is involved in the repair of single-strand breaks in DNA. When PARP is inhibited, these single-strand breaks can accumulate and lead to double-strand breaks, which are more lethal to cells. In cancer cells that are deficient in homologous recombination repair, such as those with BRCA1 or BRCA2 mutations, the accumulation of DNA damage can lead to cell death. This makes Senaparib particularly effective in treating cancers with these genetic deficiencies.

Clinical Development

Senaparib is currently undergoing clinical trials to evaluate its efficacy and safety in various cancer types. It is being studied both as a monotherapy and in combination with other anticancer agents. The trials aim to determine the optimal dosing regimen and to identify patient populations that may benefit the most from Senaparib treatment.

Potential Indications

Senaparib is being investigated for use in several types of cancer, including:

• Ovarian cancer
• Breast cancer
• Prostate cancer
• Pancreatic cancer

These cancers are often associated with defects in DNA repair pathways, making them suitable targets for PARP inhibition.

Side Effects

As with other PARP inhibitors, Senaparib may cause a range of side effects. Common side effects include:

• Fatigue
• Nausea
• Anemia
• Thrombocytopenia

Patients receiving Senaparib are monitored for these side effects, and dose adjustments may be necessary to manage them.

Research and Development

The development of Senaparib is part of a broader effort to create targeted therapies that exploit specific vulnerabilities in cancer cells. By focusing on the DNA repair pathways, researchers hope to develop treatments that are more effective and have fewer side effects than traditional chemotherapy.

Related Pages

• PARP inhibitor
• BRCA1
• BRCA2
• DNA repair
• Cancer treatment